- Home
- IFRX
IFRX
InflaRx N.V.
as 03-31-2025 9:38am EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 117.8M | IPO Year: | 2017 |
| Target Price: | $9.00 | AVG Volume (30 days): | 339.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.13 - $2.81 | Next Earning Date: | 03-20-2025 |
| Revenue: | $171,642 | Revenue Growth: | 162.79% |
| Revenue Growth (this year): | 381.73% | Revenue Growth (next year): | 2277.23% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
GlobeNewswire
11 days ago
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire
24 days ago
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
GlobeNewswire
a month ago
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
GlobeNewswire
a month ago
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
GlobeNewswire
a month ago
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
MT Newswires
a month ago
Sector Update: Health Care Stocks Flat to Higher Premarket Friday
MT Newswires
a month ago
InflaRx Slumps Premarket After Pricing $30 Million Offering of Ordinary Shares, Pre-Funded Warrants
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.